Format

Send to

Choose Destination
Herz. 2017 Dec;42(8):715-720. doi: 10.1007/s00059-017-4643-5.

[Management of valvular heart disease : ESC/EACTS guidelines 2017].

[Article in German]

Author information

1
Medizinische Klinik I, Städtische Kliniken Neuss, Lukaskrankenhaus GmbH, Preußenstr. 84, 41464, Neuss, Deutschland. mhaude@lukasneuss.de.

Abstract

After 5 years the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery have released an update on the guidelines for the management of valvular heart diseases. In recent years published results of randomized trials in patients with aortic valve stenosis have resulted in updated recommendations for catheter-based prosthesis implantation (TAVI), which is now extended to patients presenting without a low risk for conventional surgical valve replacement. In mitral or tricuspid valvular disease, the recommendations for catheter-based therapies are less strong because of a lack of supportive scientific data. A special focus of these updated guidelines is on concomitant antithrombotic therapy in valvular heart disease and in the context of a combination with coronary artery disease and/or accompanying arrhythmia. Special emphasis was again put on the multidisciplinary heart team for the diagnostics and treatment of patients with valvular heart disease. In order to support the quality of treatment for patients with valvular heart disease, it is suggested that heart valve centers of excellence should be established, which have to fulfil complex personnel, structural and technological prerequisites.

KEYWORDS:

Antithrombotic therapy; Heart team; Heart valve centers of excellence; Heart valves; Transcatheter aortic valve replacement

PMID:
29188357
DOI:
10.1007/s00059-017-4643-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center